TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy [Yahoo! Finance]
Protara Therapeutics, Inc. (TARA)
Company Research
Source: Yahoo! Finance
of its ongoing mid-stage study evaluating intravesical TARA-002 for treating non-muscle invasive bladder cancer (NMIBC). TARA-002 is Protara's investigational cell therapy, which is currently in development for treating NMIBC and lymphatic malformations (LMs). The candidate enjoys the FDA's Rare Pediatric Disease designation for treating these indications in the United States. Patients enrolled in the ongoing phase II ADVANCED-2 study were high-risk NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naïve. NMIBC patients treated with TARA-002 achieved a complete response (CR) rate of 72% at six months and 70% at any time across BCG exposures with 100% of patients maintaining a CR from three months to six months. Protara also reported that two out of three treated patients maintained a CR at nine months. In the past three months, shares of TARA have skyrocketed 227.2% against the industry's 7.3% decline. Image Sou
Show less
Read more
Impact Snapshot
Event Time:
TARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARA alerts
High impacting Protara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TARA
News
- Protara Announces Closing of $100 Million Public OfferingGlobeNewswire
- Protara Announces Pricing of $100 Million Public OfferingGlobeNewswire
- Protara Announces Proposed Public Offering [Yahoo! Finance]Yahoo! Finance
- Protara Announces Proposed Public OfferingGlobeNewswire
- Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most [Yahoo! Finance]Yahoo! Finance
TARA
Earnings
- 11/12/24 - In-Line
TARA
Sec Filings
- 12/17/24 - Form SC
- 12/11/24 - Form 8-K
- 12/11/24 - Form 424B5
- TARA's page on the SEC website